Array BioPharma to Present at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Confere

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Conference. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.

   

Event:

Stifel Nicolaus Healthcare Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Thursday, September 18, 2011

Time:

11:30 a.m. Eastern Time

Location:

Four Seasons, Boston, MA

Webcast:

www.arraybiopharma.com

 

Event:

Rodman & Renshaw Global Investment Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Monday, September 12, 2011

Time:

10:50 a.m. Eastern Time

Location:

The Waldorf=Astoria, New York, NY

Webcast:

www.arraybiopharma.com

 

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.